Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.

@article{Chen2017DiagnosticAP,
  title={Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.},
  author={Zhongjian Chen and Giovanni Gaudino and Harvey I. Pass and Michele Carbone and Haining Yang},
  journal={Translational lung cancer research},
  year={2017},
  volume={6 3},
  pages={
          259-269
        }
}
Malignant mesothelioma (MM) is an aggressive and lethal cancer, mostly related to inhalation of asbestos and erionite fibers. MM is associated with poor prognosis, because of its resistance to current therapies, even if higher survival occurs in patients diagnosed and treated when at stage I of the disease. However, these do not exceed 5% of the total number of cases, due to the inadequacy of the existing biomarkers for early and accurate diagnosis. Therefore, new effective biomarkers are… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology • 2018
View 1 Excerpt